ARTICLE | Top Story
venBio closes $315M fund
May 6, 2016 1:45 AM UTC
venBio closed its Global Strategic Fund II with $315 million, above its initial target of $250 million. Strategic LPs Amgen Inc. (NASDAQ:AMGN), Merck & Co. Inc. (NYSE:MRK) and Baxalta Inc. (NYSE:BXLT) contributed most of the fund's money. Baxalta, then part of Baxter International Inc. (NYSE:BAX), and Amgen were LPs in venBio's Fund I. ...